Cited by 40Viral Infectious Diseases and Gene Expression in InsectsProtein purification and stabilityVirus-based gene therapy research

Anti-apoptotic genes Aven and E1B-19K enhance performance of BHK cells engineered to express recombinant factor VIII in batch and low perfusion cell culture

Nivitchanyong, Toey, Martinez, Amanda, Ishaque, Adiba, Murphy, John E., Konstantinov, Konstantin, Betenbaugh, Michael J., Thrift, John·2007·Biotechnology and Bioengineering

Abstract

The engineering of production cell lines to express anti‐apoptotic genes has been pursued in recent years due to potential process benefits, including enhanced cell survival, increased protein expression, and improved product quality. In this study, a baby hamster kidney cell line secreting recombinant factor VIII (BHK‐FVIII) was engineered to express the anti‐apoptotic genes Aven and E1B‐19K. In high cell density shake flask culture evaluation, 11 clonal cell lines expressing either E1B‐19K or a combination of Aven and E1B‐19K showed improved survival compared to both parental and blank vector cell line controls. These cell lines exhibited lower caspase‐3 activation and reduced Annexin‐V binding compared to the controls. Parental and blank vector cell lines were less than 50% viable after 48 h of exposure to thapsigargin while cell lines expressing E1B‐19K with or without Aven maintained viabilities approaching 90%. Subsequently, the best Aven‐E1B‐19K candidate cell line was compared to the parental cell line in 12‐L perfusion bioreactor studies. Choosing the appropriate perfusion rates in bioreactors is a bioprocess optimization issue, so the bioreactors were operated at sequentially lower specific perfusion rates, while maintaining a cell density of 2 × 10 7 viable cells/mL. The viability of the parental cell line declined from nearly 100% at a perfusion rate of 0.5 nL/cell/day to below 80% viability, with caspase‐3 activity exceeding 15%, at its lower perfusion limit of 0.15 nL/cell/day. In contrast, the Aven‐E1B‐19K cell line maintained an average viability of 94% and a maximum caspase‐3 activity of 2.5% even when subjected to a lower perfusion minimum of 0.1 nL/cell/day. Factor VIII productivity, specific growth rate, and cell size decreased for both cell lines at lower perfusion rates, but the drop in all cases was larger for the parental cell line. Specific consumption of glucose and glutamine and production of lactate were consistently lower for the Aven‐E1B‐19K culture. Furthermore, the yield of ammonia from glutamine increased for the Aven‐E1B‐19K cell line relative to the parent to suggest altered metabolic pathways following anti‐apoptosis engineering. These results demonstrate that expression of anti‐apoptotic genes Aven and E1B‐19K can increase the stability and robustness of an industrially relevant BHK‐FVIII mammalian cell line over a wide range of perfusion rates. Biotechnol. Bioeng. 2007; 98: 825–841. © 2007 Wiley Periodicals, Inc.

Integrity signals

Registry

Crossref · 10.1002/bit.21479

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Factor VIIa and Factor VIII are abundantly glycosylated and sulfated and are thus challenging to manufacture.

    “These large glycoproteins are abundantly glycosylated and sulfated and are thus challenging to manufacture (Soukharev et al., 2002;Ishaque et al., 2007;Nivitchanyong et al., 2007).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Nivitchanyong et al., 2007

Cited by

Sorted by citations

Authors
Nivitchanyong, T., Martinez, A., Ishaque, A., Murphy, J. E., Konstantinov, K., Betenbaugh, M. J., & Thrift, J.
Affiliations
Johns Hopkins University (US)
Corresponding author
Betenbaugh, Michael J.
Venue
Biotechnology and Bioengineering
Publisher
Wiley
Published
2007-05-18
Volume
98
Issue
4
Pages
825-841
ISSN
  • 0006-3592 (ISSN-L)
  • 1097-0290
OpenAlex
W2145525974
Cited by
40
References
0
Citations by year
2025: 1 · 2022: 1 · 2020: 1 · 2017: 3 · 2015: 1 · 2014: 3 · 2013: 6 · 2012: 2
FWCI
1.19
Type
journal article
Language
en
Open access
closed
Locations
  • Biotechnology and Bioengineering (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
anti-apoptotic genes, Aven, recombinant factor VIII, BHK cells, cell viability, caspase-3 activation, thapsigargin, perfusion bioreactor, cell growth kinetics, ammonia yield, recombinant protein expression, cell line engineering, bioprocess optimization
MeSH terms
Animals, Cell Line, Factor VIII, Cricetinae, Kidney, Membrane Proteins, Perfusion, Recombinant Proteins, Viral Proteins, Protein Engineering, Apoptosis, Cell Culture Techniques, Genetic Enhancement, Adaptor Proteins, Signal Transducing, Apoptosis Regulatory Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review